Mike Sharland
Overview
Explore the profile of Mike Sharland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
265
Citations
5087
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hill L, Obiero C, Bekker A, Walker A, Bielicki J, Sharland M, et al.
Trials
. 2025 Feb;
26(1):46.
PMID: 39924475
Adverse event (AE) collection is a key part of evidence generation in clinical trials and an integral element of safety reporting. AE assessment and documentation is particularly challenging in neonates...
2.
Pillay K, Ray-Chaudhuri A, OBrien S, Heath P, Sharland M
Front Antibiot
. 2025 Jan;
3():1448071.
PMID: 39816262
Neonatal sepsis causes substantial morbidity and mortality, the burden of which is carried by low-income countries (LICs). The emergence of multidrug-resistant pathogens in vulnerable neonatal populations poses an urgent threat...
3.
Malani A, Sharland M, Clancy C, Skov R
Open Forum Infect Dis
. 2024 Nov;
11(11):ofae522.
PMID: 39582507
No abstract available.
4.
Harrison M, Dickson B, Sharland M, Williams P
Pediatr Infect Dis J
. 2024 Sep;
PMID: 39264197
Sepsis remains a leading cause of neonatal mortality, particularly in low- and lower-middle-income countries (LLMIC). In the context of rising antimicrobial resistance, the etiology of neonatal sepsis is evolving, potentially...
5.
Mendelson M, Lewnard J, Sharland M, Cook A, Pouwels K, Alimi Y, et al.
Lancet
. 2024 May;
403(10443):2551-2564.
PMID: 38797179
Rising antimicrobial resistance (AMR) is a global health crisis for countries of all economic levels, alongside the broader challenge of access to antibiotics. As a result, development goals for child...
6.
Okeke I, de Kraker M, Van Boeckel T, Kumar C, Schmitt H, Gales A, et al.
Lancet
. 2024 May;
403(10442):2426-2438.
PMID: 38797176
Each year, an estimated 7·7 million deaths are attributed to bacterial infections, of which 4.95 million are associated with drug-resistant pathogens, and 1·27 million are caused by bacterial pathogens resistant...
7.
Bamford A, Masini T, Williams P, Sharland M, Gigante V, Dixit D, et al.
Lancet Child Adolesc Health
. 2024 Apr;
8(6):456-466.
PMID: 38648808
Children and neonates are highly vulnerable to the impact of antimicrobial resistance. Substantial barriers are faced in relation to research and development of antibacterial agents for use in neonates, children,...
8.
Knowles R, Chandler C, ONeill S, Sharland M, Mays N
J Antimicrob Chemother
. 2024 Mar;
79(6):1234-1247.
PMID: 38507232
Objectives: To identify and assess the effectiveness of national antibiotic optimization interventions in primary and secondary care in England (2013-2022). Methods: A systematic scoping review was conducted. Literature databases (Embase...
9.
Sinto R, Lie K, Setiati S, Suwarto S, Nelwan E, Karyanti M, et al.
PLoS One
. 2024 Mar;
19(3):e0297405.
PMID: 38452030
Background: Little is known about diagnostic and antibiotic use practices in low and middle-income countries (LMICs) before and during COVID-19 pandemic. This information is crucial for monitoring and evaluation of...
10.
Reza N, Gerada A, Stott K, Howard A, Sharland M, Hope W
Clin Microbiol Rev
. 2024 Mar;
37(2):e0013923.
PMID: 38436564
SUMMARYThe World Health Organisation's 2022 AWaRe Book provides guidance for the use of 39 antibiotics to treat 35 infections in primary healthcare and hospital facilities. We review the evidence underpinning...